Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Forecast 2026-2035

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Forecast Report Coverage

Expert Market Research's “Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Hereditary Transthyretin Amyloidosis (hATTR). It projects the future incidence and prevalence rates of Hereditary Transthyretin Amyloidosis (hATTR) cases across various populations. The study covers age, gender, and type as major determinants of the Hereditary Transthyretin Amyloidosis (hATTR) population. The report highlights patterns in the prevalence of Hereditary Transthyretin Amyloidosis (hATTR) over time and projects future trends based on multiple variables.

Hereditary Transthyretin Amyloidosis (hATTR) Understanding: Disease Overview

Hereditary Transthyretin Amyloidosis (hATTR) is a rare, progressive and potentially fatal multisystem disease caused by pathogenic variants in the transthyretin (TTR) gene, resulting in the deposition of misfolded transthyretin amyloid fibrils in peripheral nerves, heart and other organs. Clinical manifestations commonly include progressive sensorimotor and autonomic polyneuropathy, cardiomyopathy, gastrointestinal dysfunction, renal involvement, ocular disease and musculoskeletal complications.

Key Report Insights

Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Perspective

The Hereditary Transthyretin Amyloidosis (hATTR) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Hereditary Transthyretin Amyloidosis (hATTR) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Hereditary Transthyretin Amyloidosis (hATTR) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Country-wise Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology

The Hereditary Transthyretin Amyloidosis (hATTR) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The principal market gap is delayed and inconsistent diagnosis, particularly in patients presenting without a recognized family history or with nonspecific neuropathy, cardiomyopathy, autonomic dysfunction, or mixed manifestations. A 2025 study reported a median diagnostic delay of 1,262 days among apparently sporadic ATTRv patients. In France, experts have additionally identified non-standardized genetic-testing pathways, communication gaps and regulatory complexity as barriers to timely diagnosis. A major untapped opportunity is therefore systematic genetic and cascade screening of high-risk populations and relatives of confirmed patients. Contemporary evidence shows that screening can identify clinically silent carriers and early organ involvement before advanced disease develops. In a 2025 prospective cascade-screening study, 20.5% of asymptomatic relatives carried a pathogenic TTR variant without scintigraphic cardiac involvement, while 8.2% already had detectable cardiac amyloidosis. A 2026 Italian multicentre study similarly found that cascade testing of relatives identified hundreds of previously unrecognized carriers and enabled earlier clinical diagnosis.

Hereditary Transthyretin Amyloidosis (hATTR): Treatment Overview

Treatment of hereditary transthyretin amyloidosis (hATTR/ATTRv) has shifted from predominantly supportive management toward disease-modifying suppression of transthyretin production and stabilization of circulating TTR tetramers. Current international guidance recommends TTR gene silencers or tetramer stabilizers for appropriate symptomatic patients, with treatment selection determined primarily by the dominant phenotype polyneuropathy, cardiomyopathy, or mixed disease and by local regulatory approvals. Early treatment is important because existing therapies generally slow or stabilize progression rather than restore established organ damage. TTR gene silencers constitute the most important expanding treatment class for ATTRv. Small-interfering RNA (siRNA) therapies such as patisiran and vutrisiran and the antisense oligonucleotides inotersen and eplontersen reduce hepatic production of both mutant and wild-type TTR.

Key Questions Answered

• What is the current and projected burden of Hereditary Transthyretin Amyloidosis (hATTR) across the 8 major markets?
• Which countries across the 8 major markets account for the highest Hereditary Transthyretin Amyloidosis (hATTR) patient populations and fastest growth rates?
• What is the diagnosed versus undiagnosed patient population of Hereditary Transthyretin Amyloidosis (hATTR) across key countries in the 8 major markets?
• Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Hereditary Transthyretin Amyloidosis (hATTR) across the 8 major markets?
• What are the major drivers contributing to the increasing burden of Hereditary Transthyretin Amyloidosis (hATTR) across the 8 major markets?
• How do major comorbidities and risk factors influence Hereditary Transthyretin Amyloidosis (hATTR) epidemiology trends across the 8 major markets?
• What are the regional trends in advanced disease progression, treatment uptake, and patient management of Hereditary Transthyretin Amyloidosis (hATTR) across the 8 major markets?
• Which patient segments represent the highest unmet clinical need in the Hereditary Transthyretin Amyloidosis (hATTR) landscape across the 8 major markets?
• Which therapeutic areas linked to Hereditary Transthyretin Amyloidosis (hATTR) are expected to witness the strongest growth opportunities across the 8 major markets?
• How is the Hereditary Transthyretin Amyloidosis (hATTR) epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
• Which countries across the 8 major markets offer the most attractive market opportunities based on Hereditary Transthyretin Amyloidosis (hATTR) epidemiology and healthcare infrastructure?
• Which epidemiological trends are expected to influence future drug development and market access strategies for Hereditary Transthyretin Amyloidosis (hATTR) across the 8 major markets?

Scope of the Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Hereditary Transthyretin Amyloidosis (hATTR) based on several factors.
• Hereditary Transthyretin Amyloidosis (hATTR) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The Hereditary Transthyretin Amyloidosis (hATTR) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Nerve Repair and Regeneration Market

Amyloidosis Market